Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(4):173-176; doi:10.1093/jjco/hyi058
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kodaira, T.
Right arrow Articles by Yamazaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kodaira, T.
Right arrow Articles by Yamazaki, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Phase I Trial of Weekly Docetaxel and Concurrent Radiotherapy for Head and Neck Cancer in Elderly Patients or Patients with Complications

Takeshi Kodaira, Nobukazu Fuwa, Kazuhisa Furutani, Hiroyuki Tachibana and Takuya Yamazaki

Department of Therapeutic Radiation Oncology, Aichi Cancer Center, Nagoya, Japan

For reprints and all correspondence: Takeshi Kodaira, Department of Therapeutic Radiation Oncology, Aichi Cancer Center, 1-1 Kanokoden Chikusa-ku, 464-8681 Nagoya, Aichi, Japan. E-mail: 109103{at}aichi-cc.jp

Received December 10, 2004; accepted February 14, 2005

Objective: We planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose.

Methods: Five consecutive weekly administrations of docetaxel were accompanied by radiotherapy for patients diagnosed with squamous cell carcinoma of the head and neck. The starting dose of docetaxel was 10 mg/m2 with escalation at 2 mg/m2 per step.

Results: Fifteen patients were enrolled in this trial. The maximal tolerated dose was 14 mg/m2, so the recommended dose was determined as 12 mg/m2. Hematological toxicity was sufficiently weak. Common dose-limiting toxicity was stomatitis within the radiation field.

Conclusions: This protocol was thought to be practical for elderly patients or those with medical complications.

Key Words: elderly patients • concurrent • docetaxel • head and neck • radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
Y. Kitamoto, T. Akimoto, H. Ishikawa, T. Nonaka, H. Katoh, T. Nakano, H. Ninomiya, K. Chikamatsu, and N. Furuya
Acute Toxicity and Preliminary Clinical Outcomes of Concurrent Radiation Therapy and Weekly Docetaxel and Daily Cisplatin for Head and Neck Cancer
Jpn. J. Clin. Oncol., November 1, 2005; 35(11): 639 - 644.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.